Peptide
VIP Peptide
SaveVasoactive Intestinal Peptide, a 28-amino-acid neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties. Studied for CIRS, pulmonary hypertension, and inflammatory conditions.
Quick verdict
Well-characterized neuropeptide with diverse biology. Used off-label for chronic inflammatory response syndrome (CIRS) by some practitioners. Clinical trial data are limited but a few exist for pulmonary conditions.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Small clinical trials for pulmonary hypertension and sarcoidosis. Off-label CIRS use promoted by Shoemaker protocol but not validated in large RCTs. Broad anti-inflammatory preclinical data.
Benefits
- Anti-inflammatory and immunomodulatory effects well characterized
- Small clinical trials for pulmonary hypertension
- Inhaled delivery route avoids some systemic side effects
Dosage notes
Inhaled: 50 mcg 4 times daily (Shoemaker CIRS protocol). Clinical trials have used IV infusion. No standardized dosing.
Side effects
- Hypotension
- Diarrhea
- Flushing
- Nasal congestion with inhaled use
Who should be cautious
Potent vasodilator — hypotension risk. Not FDA-approved for any indication. Off-label use is controversial.
What this page cannot tell you
CIRS use is based on one practitioner's protocol without rigorous trial validation. Pulmonary data are from small studies.
Leaderboard scores
- Immunity30
- Stress20
- Pain18
Write a review
Sign in to write a review.